Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Ernexa Therapeutics Inc. (ERNA : NSDQ)
 
 • Company Description   
Ernexa Therapeutics is developing cell therapies for the treatment of advanced cancer and autoimmune disease. Ernexa Therapeutics, formerly known as Eterna Therapeutics, is based in CAMBRIDGE, Mass.

Number of Employees: 6

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.98 Daily Weekly Monthly
20 Day Moving Average: 98,571 shares
Shares Outstanding: 7.36 (millions)
Market Capitalization: $14.58 (millions)
Beta: 5.30
52 Week High: $39.38
52 Week Low: $1.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -16.46% -19.58%
12 Week -28.61% -39.95%
Year To Date -55.08% -57.93%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1035 CAMBRIDGE STREET SUITE 18A
-
CAMBRIDGE,MA 02141
USA
ph: 212-582-1199
fax: 760-438-3505
investors@eternatx.com http://www.eternatx.com
 
 • General Corporate Information   
Officers
Sanjeev Luther - President and Chief Executive Officer and Director
James Bristol - Chairman of the Board
Sandra Gurrola - Senior Vice President; Finance
Peter Cicala - Director
Elena Ratner - Director

Peer Information
Ernexa Therapeutics Inc. (GSAC)
Ernexa Therapeutics Inc. (CASI)
Ernexa Therapeutics Inc. (ALCD.)
Ernexa Therapeutics Inc. (OMNN)
Ernexa Therapeutics Inc. (CGPI.)
Ernexa Therapeutics Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 114082308
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/12/25
Share - Related Items
Shares Outstanding: 7.36
Most Recent Split Date: 6.00 (0.07:1)
Beta: 5.30
Market Capitalization: $14.58 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/12/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: 25.06
EPS Growth
vs. Year Ago Period: 87.80%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -94.12%
vs. Previous Quarter: -99.79%
ROE
06/30/25 - -
03/31/25 - -
12/31/24 - -
ROA
06/30/25 - -
03/31/25 - -285.71
12/31/24 - -163.25
Current Ratio
06/30/25 - -
03/31/25 - 0.21
12/31/24 - 0.80
Quick Ratio
06/30/25 - -
03/31/25 - 0.21
12/31/24 - 0.80
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -7,652.75
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -7,652.75
Pre-Tax Margin
06/30/25 - -
03/31/25 - -8,609.35
12/31/24 - -7,647.59
Book Value
06/30/25 - -
03/31/25 - -1.43
12/31/24 - 0.50
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - -
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©